Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Joseph Michaeli"'
Publikováno v:
Cancer Investigation. 20:1051-1058
Multiple myeloma (MM) is a malignant clonal proliferation of plasma cells characterized by the excessive production of a single immunoglobulin protein isotype. In the year 2000, approximately 13,800 new cases of MM were diagnosed in the United States
Autor:
Joseph Michaeli, Ruben Niesvizky, David J. Straus, Larry Lyons, Jill R. Glassman, Jacqueline Fine, David S. Siegel
Publikováno v:
Leukemia & Lymphoma. 43:607-612
We report the results of a dose-intense chemotherapy regimen designed to rapidly induce remissions in patients with advanced multiple myeloma (MM). Patients received VAD for 3-6 cycles depending on response kinetics. This was followed by three sequen
Autor:
Joseph Michaeli, M. Jose Calasanz, R. S. K. Chaganti, Pulivarthi H. Rao, M. Dolores Odero, Suresh C. Jhanwar, Juan C. Cigudosa
Publikováno v:
Blood. 91:3007-3010
Clonal chromosomal changes in multiple myeloma (MM) and related disorders are not well defined, mainly due to the low in vivo and in vitro mitotic index of plasma cells. This difficulty can be overcome by using comparative genomic hybridization (CGH)
Publikováno v:
Clinical Immunotherapeutics. 4:346-360
Autor:
D. Siegel, Philip H. Lieberman, Joseph Michaeli, Daniel A. Filippa, Ruben Niesvizky, Marc Ladanyi
Publikováno v:
Blood. 86:1159-1162
Proteinaceous lymphadenopathy with hypergammaglobulinemia (PLWH) is an exceedingly rare disease of unknown etiology. Described primarily as a pathologic entity, relatively little is known about its clinical manifestations or its response to therapy.
Publikováno v:
Leukemia & Lymphoma. 43:603-605
Adjunctive anti-bone resorption therapy has become an important part of multiple myeloma (MM) treatment. Currently, no definite evidence exists that this therapy increases survival. We examined a cohort of 13 of 167 patients (8%) treated with the M-2
Autor:
William P. Tong, Donald Kufe, Michael Andreeff, Joseph Michaeli, H. Sogoloff, Richard Stone, Paul A. Marks, Richard A. Rifkind, T. Ervin, Charles W. Young
Publikováno v:
Blood. 80:2604-2609
Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro. We report results of a phase II clinical trial in 41 patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (
Publikováno v:
Acta Haematologica. 87:71-74
Thromboembolic complications in beta-thalassemia major have seldom been reported and their association with risk factors such as left ventricular failure and postsplenectomy thrombocytosis has remained speculative. In this report we describe 4 patien
Publikováno v:
Leukemia. 13:2118-2120
Autor:
Charles A. Mack, Jerome J. DeCosse, Monica M. Bertagnolli, Joseph Michaeli, Najjia N. Mahmoud
Publikováno v:
Surgery. 125:236-238